Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E2-independent mechanisms

Cancer Letters

Volumn 256, Issue 2, 2007, Pages 246-258

  Deasy, B M ^a   O'Sullivan Coyne, G ^a   O'Donovan, T R ^a   Mckenna, S L ^a   O'Sullivan, G C ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

COX 2; Oesophageal cancer; Prevention

Indexed keywords

CASPASE 3; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN E2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL STRUCTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG MECHANISM; DRUG TARGETING; ENZYME ACTIVITY; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; HISTOLOGY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SHAPE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; DINOPROSTONE; DOSE-RESPONSE RELATIONSHIP, DRUG; ESOPHAGEAL NEOPLASMS; HUMANS; MITOCHONDRIAL MEMBRANES; NITROBENZENES; SULFONAMIDES; TIME FACTORS;

EID: 34548709664     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2007.06.013     Document Type: Article

References (52)

1. Conio M., Lapertosa G., Blanchi S., and Filiberti R. Barrett's esophagus: an update. Crit. Rev. Oncol. Hematol. 46 (2003) 187-206
2. Altorki N.K., Oliveria S., and Schrump D.S. Epidemiology and molecular biology of Barrett's adenocarcinoma. Semin. Surg. Oncol 13 (1997) 270-280
3. Harris R.E., Beebe-Donk J., Doss H., and Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol. Rep. 13 (2005) 559-583
4. Husain S.S., Szabo I.L., and Tamawski A.S. NSAID inhibition of GI cancer growth: clinical implications and molecular mechanisms of action. Am. J. Gastroenterol. 97 (2002) 542-553
5. Chan T.A. Nonsteroidal anti-inflammatory drugs, apoptosis, and colon-cancer chemoprevention. Lancet Oncol. 3 (2002) 166-174
6. Rubio C.A. Antitumoral activity of indomethacin on experimental esophageal tumors. J. Natl. Cancer. Inst. 72 (1984) 705-707
7. Rubio C.A. Further studies on the therapeutic effect of indomethacin on esophageal tumors. Cancer 58 (1986) 1029-1031
8. Buttar N.S., Wang K.K., Leontovich O., Westcott J.Y., Pacifico R.J., Anderson M.A., et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology 122 (2002) 1101-1112
9. Stoner G.D., Qin H., Chen T., Carlton P.S., Rose M.E., Aziz R.M., et al. The effects of L-748706, a selective cyclooxygenase-2 inhibitor, on N-nitrosomethylbenzylamine-induced rat esophageal tumorigenesis. Carcinogenesis 26 (2005) 1590-1595
10. Dannenberg A.J., Altorki N.K., Boyle J.O., Dang C., Howe L.R., Weksler B.B., et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2 (2001) 544-551
11. Zimmermann K.C., Sarbia M., Weber A.A., Borchard F., Gabbert H.E., and Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res. 59 (1999) 198-204
12. Shamma A., Yamamoto H., Doki Y., Okami J., Kondo M., Fujiwara Y., et al. Up-regulation of cyclooxygenase-2 in squamous carcinogenesis of the esophagus. Clin. Cancer Res. 6 (2000) 1229-1238
13. Yu H.P., Xu S.Q., Liu L., Shi L.Y., Cai X.K., Lu W.H., et al. Cyclooxygenase-2 expression in squamous dysplasia and squamous cell carcinoma of the esophagus. Cancer Lett. 198 (2003) 193-201
14. Kaur B.S., Khamnehei N., Iravani M., Namburu S.S., Lin O., and Triadafilopoulos G. Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus. Gastroenterology 123 (2002) 60-67
15. Tuynman J.B., Buskens C.J., Kemper K., ten Kate F.J., Offerhaus G.J., Richel D.J., et al. Neoadjuvant selective COX-2 inhibition down-regulates important oncogenic pathways in patients with esophageal adenocarcinoma. Ann. Surg. 242 (2005) 840-849 discussion 849-850
16. Buttar N.S., Wang K.K., Anderson M.A., Dierkhising R.A., Pacifico R.J., Krishnadath K.K., et al. The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium: an in vitro study. J. Natl. Cancer Inst. 94 (2002) 422-429
17. Tsujii M., and DuBois R.N. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83 (1995) 493-501
18. Lagorce C., Paraf F., Vidaud D., Couvelard A., Wendum D., Martin A., et al. Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma. Histopathology 42 (2003) 457-465
19. Kuramochi H., Vallbohmer D., Uchida K., Schneider S., Hamoui N., Shimizu D., et al. Quantitative, tissue-specific analysis of cyclooxygenase gene expression in the pathogenesis of Barrett's adenocarcinoma. J. Gastrointest. Surg. 8 (2004) 1007-1016
20. Morris C.D., Armstrong G.R., Bigley G., Green H., and Attwood S.E. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. Am. J. Gastroenterol. 96 (2001) 990-996
21. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., Omary M.B., and Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: Ex vivo induction by bile salts and acid exposure. Gastroenterology 118 (2000) 487-496
22. Zhang X., Miao X., Tan W., Ning B., Liu Z., Hong Y., et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 129 (2005) 565-576
23. Hung W.C., Chang H.C., Pan M.R., Lee T.H., and Chuang L.Y. Induction of p27(KIP1) as a mechanism underlying NS398-induced growth inhibition in human lung cancer cells. Mol. Pharmacol. 58 (2000) 1398-1403
24. Liu X.H., Yao S., Kirschenbaum A., and Levine A.C. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 58 (1998) 4245-4249
25. Cheong E., Ivory K., Doleman J., Parker M.L., Rhodes M., and Johnson I.T. Synthetic and naturally occurring COX-2 inhibitors suppress proliferation in a human oesophageal adenocarcinoma cell line (OE33) by inducing apoptosis and cell cycle arrest. Carcinogenesis 25 (2004) 1945-1952
26. Souza R.F., Shewmake K., Beer D.G., Cryer B., and Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60 (2000) 5767-5772
27. Vona-Davis L., Riggs D.R., Jackson B.J., and McFadden D.W. Antiproliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro (1). J. Surg. Res. 119 (2004) 143-148
28. Yu H.P., Shi L.Y., Lu W.H., Su Y.H., Li Y.Y., and Xu S.Q. Expression of cyclooxygenase-2 (COX-2) in human esophageal cancer and in vitro inhibition by a specific COX-2 inhibitor, NS-398. J. Gastroenterol. Hepatol. 19 (2004) 638-642
29. Barnett J., Chow J., Ives D., Chiou M., Mackenzie R., Osen E., et al. Purification, characterization and selective inhibition of human prostaglandin G/H synthase 1 and 2 expressed in the baculovirus system. Biochim. Biophys. Acta 1209 (1994) 130-139
30. Hida T., Kozaki K., Muramatsu H., Masuda A., Shimizu S., Mitsudomi T., et al. Cyclooxygenase-2 inhibitor induces apoptosis and enhances cytotoxicity of various anticancer agents in non-small cell lung cancer cell lines. Clin. Cancer Res. 6 (2000) 2006-2011
31. Davis R., and Brogden R.N. Nimesulide. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 48 (1994) 431-454
32. Minter H.A., Eveson J.W., Huntley S., Elder D.J., and Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin. Cancer Res. 9 (2003) 1885-1897
33. Rockett J.C., Larkin K., Darnton S.J., Morris A.G., and Matthews H.R. Five newly established oesophageal carcinoma cell lines: phenotypic and immunological characterization. Br. J. Cancer 75 (1997) 258-263
34. Collins J.K., O'Mahony A., O'Brien F., Corbett A., Morrissey D., O'Donoghue M., et al. Evaluation of newly established cell lines as models to study growth, invasion and metastasis spread in oesophageal cancer. Fibrinolysis 6 (1992) 83-88
35. Agarwal B., Swaroop P., Protiva P., Raj S.V., Shirin H., and Holt P.R. Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells. Apoptosis 8 (2003) 649-654
36. Elder D.J., Halton D.E., Crew T.E., and Paraskeva C. Apoptosis induction and cyclooxygenase-2 regulation in human colorectal adenoma and carcinoma cell lines by the cyclooxygenase-2-selective non-steroidal anti-inflammatory drug NS-398. Int. J. Cancer 86 (2000) 553-560
37. Jia X.Q., Zhong N., Han L.H., Wang J.H., Yan M., Meng F.L., et al. Effect of NS-398 on colon cancer cells. World J. Gastroenterol. 11 (2005) 353-356
38. Richter M., Weiss M., Weinberger I., Furstenberger G., and Marian B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 22 (2001) 17-25
39. Shaik M.S., Chatterjee A., and Singh M. Effect of a selective cyclooxygenase-2 inhibitor, nimesulide, on the growth of lung tumors and their expression of cyclooxygenase-2 and peroxisome proliferator- activated receptor-gamma. Clin. Cancer Res. 10 (2004) 1521-1529
40. Yamazaki R., Kusunoki N., Matsuzaki T., Hashimoto S., and Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 531 (2002) 278-284
41. Chang H.C., and Weng C.F. Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells. Oncol. Rep. 8 (2001) 1321-1325
42. Maier T.J., Schilling K., Schmidt R., Geisslinger G., and Grosch S. Cyclooxygenase-2 (COX-2)-dependent and -independent anticarcinogenic effects of celecoxib in human colon carcinoma cells. Biochem. Pharmacol. 67 (2004) 1469-1478
43. Smith M.L., Hawcroft G., and Hull M.A. The effect of non-steroidal anti-inflammatory drugs on human colorectal cancer cells: evidence of different mechanisms of action. Eur. J. Cancer 36 (2000) 664-674
44. Piazza G.A., Alberts D.S., Hixson L.J., Paranka N.S., Li H., Finn T., et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 57 (1997) 2909-2915
45. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23 (2002) 144-150
46. Yao M., Lam E.C., Kelly C.R., Zhou W., and Wolfe M.M. Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer. Br. J. Cancer 90 (2004) 712-719
47. Husain S.S., Szabo I.L., Pai R., Soreghan B., Jones M.K., and Tarnawski A.S. MAPK (ERK2) kinase -- a key target for NSAIDs-induced inhibition of gastric cancer cell proliferation and growth. Life Sci. 69 (2001) 3045-3054
48. Sheng H., Shao J., Morrow J.D., Beauchamp R.D., and DuBois R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 58 (1998) 362-366
49. Yamamoto Y., Yin M.J., Lin K.M., and Gaynor R.B. Sulindac inhibits activation of the NF-kappaB pathway. J. Biol. Chem. 274 (1999) 27307-27314
50. Zhang Z., and DuBois R.N. Par-4, a proapoptotic gene, is regulated by NSAIDs in human colon carcinoma cells. Gastroenterology 118 (2000) 1012-1017
51. Williams C.S., Watson A.J., Sheng H., Helou R., Shao J., and DuBois R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 60 (2000) 6045-6051
52. Grosch S., Maier T.J., Schiffmann S., and Geisslinger G. Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors. J. Natl. Cancer Inst. 98 (2006) 736-747